First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast Cancer

François-Clément Bidard

Institut Curie, Paris and Saint-Cloud; INSERM Centre d’Investigation Clinique 1428, Paris; Versailles–Saint-Quentin University, Paris–Saclay University, Saint Cloud, France

Erica L. Mayer

Yeon Hee Park

Wolfgang Janni

Cynthia Ma

Washington University School of Medicine, St. Louis

Massimo Cristofanilli

Weill-Cornell Medicine, New York–Presbyterian Hospital, New York

Giampaolo Bianchini

IRCCS Ospedale San Raffaele, Milan

Kevin Kalinsky

Winship Cancer Institute, Emory University, Atlanta

Hiroji Iwata

Nagoya City University, Nagoya, Japan

Stephen Chia

BC Cancer Agency, Vancouver, Canada

Peter A. Fasching

Adam Brufsky

Hillman Cancer Center, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh

Zbigniew Nowecki

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Warsaw, Poland

Javier Pascual

Hospital Universitario Virgen de la Victoria, Málaga, Spain

Lionel Moreau

Pôle Santé République, Clermont-Ferrand, France

Shin-Cheh Chen

Chang Gung Medical Foundation Linkou Branch, Taoyuan City, Taiwan

Nuri Karadurmus

Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey

Einav Nili Gal-Yam

Sheba Medical Center, Ramat Gan, Israel

Kyung Hae Jung

Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Sonia Pernas

Institut Català d’Oncologia–Institut d’Investigació Biomèdica de Bellvitge, L’Hospitalet, Barcelona

Sasha McClain

AstraZeneca, Gaithersburg, MD

Wei He

Teresa Klinowska

AstraZeneca, Cambridge, United Kingdom

Cynthia Huang-Bartlett

AstraZeneca, Gaithersburg, MD

Nicholas C. Turner